PET Study of M4 Muscarinic Acetylcholine Receptor Occupancy by BMS-986521 in Healthy Adult Participants

The primary objective is to assess occupancy of M4 muscarinic acetylcholine receptors by BMS-986521 in healthy adult participants, which is relevant for characterizing target engagement in relation to neuropsychiatric indications and potentially other conditions. No secondary objectives are specified.

The sponsor did not provide information on the total number of participants or on the selection of the trial population. The study population included healthy volunteers of both female and male sex. The available age information indicates a pediatric age range. No additional details were provided regarding general health status, lifestyle considerations, or inclusion or exclusion criteria.

The study is a Phase 3 clinical trial in healthy adult participants designed to assess the occupancy of M4 muscarinic acetylcholine receptors by BMS-986521. The overall trial duration is estimated from 2026-06-08 to 2026-12-23. The study plan includes a screening visit to determine eligibility before enrollment, followed by study procedures conducted according to the trial schedule, and an end-of-study visit to complete final assessments. Participant involvement is expected to last for the duration of the individual study period, from screening through the end-of-study visit. Early termination from the study may occur if eligibility criteria are not met, if a participant withdraws, or if the investigator determines that continuation is not appropriate.

No study treatments were specified in the source data.

Efficacy will be assessed in a Phase 3 clinical trial for neuropsychiatric indications and potentially other conditions.